Claims for Patent: 8,829,170

Summary for Patent: 8,829,170

Title:	Construct capable of release in closed circular form from a larger nucleotide sequence permitting site specific expression and/or developmentally regulated expression of selected genetic sequences
Abstract:	The present invention relates generally to constructs and in particular genetic constructs comprising polynucleotide sequences capable of release in covalently closed, circular form from a larger nucleotide sequence such as, but not limited to, a genome of a eukaryotic cell. Preferably, once released, a polynucleotide sequence is reconstituted in a form which permits expression of the polynucleotide sequence. In one embodiment, the reconstituted polynucleotide sequence comprises a coding sequence with all or part of an extraneous nucleotide such as, but not limited to, an intronic sequence or other splice signal inserted therein. Expression and in particular transcription of the coding sequence involves splicing out the extraneous sequence. The release and circularization is generally in response to a stimulus such as a protein-mediated stimulus. More particularly, the protein is a viral or prokaryotic or eukaryotic derived protein or developmentally and/or tissue specific regulated protein.
Inventor(s):	Dale; James Langham (Anstead, AU), Dugdale; Benjamin (Milton, AU), Hafner; Greg John (Carina, AU), Hermann; Scott Richard (Strathpine, AU), Becker; Douglas Kenneth (Alderley, AU), Harding; Robert Maxwell (Highgate Hill, AU), Chowpongpang; Srimek (Samut, TH)
Assignee:	Queensland University of Technology (Brisbane, Queensland, AU)
Application Number:	12/948,005
Patent Claims:	1. A construct system comprising: (i) a first construct comprising in 5' to 3' linear form a first Rep protein recognition sequence recognizable by a geminivirus Rep protein, the 3' end of an intron, the 3' end portion of a gene of interest operably linked to a terminator, a promoter operably linked to the 5' end of the gene of interest, the 5' end of the intron and a second Rep protein recognition sequence recognizable by the geminivirus Rep protein; wherein the Rep recognition sequences are compatible with each other to promote circularization, wherein the 3' end and the 5' end intron sequences are capable of splicing; wherein the 3' end and 5' end portions of the gene of interest together constitute the coding region of the gene of interest; wherein upon circularization, the 3' end of the intron and the 5' end of the intron form an intronic sequence, and the 5' end portion of the gene of interest is separated from said 3' end portion of the gene of interest by the intronic sequence; wherein upon excision of the intronic sequence, the 5' end portion of the gene of interest is operably linked to the 3' end portion of the gene of interest; and wherein upon expression of the gene of interest, the gene of interest exhibits an activity or property or a capacity to exhibit an activity or property not present in the separate portions of the gene of interest prior to circularization of the construct and prior to excision of the intronic sequence; and (ii) a second construct comprising a nucleotide sequence encoding the geminivirus Rep protein operably linked to a promoter. 2. The construct system of claim 1, wherein the promoter is a regulatable promoter. 3. The construct system of claim 1, wherein the promoter is an inducible promoter. 4. The construct system of claim 3, wherein the inducible promoter is an alcohol inducible promoter. 5. The construct system of claim 1, wherein the promoter is a tissue-specific promoter. 6. The construct system of claim 5, wherein the tissue-specific promoter is a seed-specific promoter. 7. The construct system of claim 5, wherein the tissue-specific promoter is a root-specific promoter. 8. The construct system of claim 1, wherein the promoter is a wound-specific promoter.

Details for Patent 8,829,170

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2020-03-28
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2020-03-28
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2020-03-28